Glatiramer acetate

Modify Date: 2024-01-04 13:03:55

Glatiramer acetate structure	Common Name	Glatiramer acetate
	CAS Number	147245-92-9	Molecular Weight	623.65000
	Density	N/A	Boiling Point	385.2ºC at 760mmHg
	Molecular Formula	(C₉H₁₁NO_3.C₆H₁₄N₂O_2.C₅H₉NO_4.C₃H₇NO₂)x_.xC₂H₄O₂	Melting Point	>239°C (dec.) (lit.)
	MSDS	N/A	Flash Point	186.7ºC

Use of Glatiramer acetate

Glatiramer acetate, a synthetic analogue of myelin basic protein and an immunomodulating agent, can be used for the research of multiple sclerosis. Glatiramer acetate exhibits strong and promiscuous binding to MHC molecules and consequent competition with various myelin antigens for their presentation to T cells. A further aspect of its action is potent induction of specific suppressor cells of the T helper 2 (Th2) type that migrate to the brain and lead to in situ bystander suppression[1][2][3].

Name	acetic acid,(2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid,(2S)-2-aminopentanedioic acid,(2S)-2-aminopropanoic acid,(2S)-2,6-diaminohexanoic acid
Synonym	More Synonyms

Description	Glatiramer acetate, a synthetic analogue of myelin basic protein and an immunomodulating agent, can be used for the research of multiple sclerosis. Glatiramer acetate exhibits strong and promiscuous binding to MHC molecules and consequent competition with various myelin antigens for their presentation to T cells. A further aspect of its action is potent induction of specific suppressor cells of the T helper 2 (Th2) type that migrate to the brain and lead to in situ bystander suppression[1][2][3].
Related Catalog	Signaling Pathways >> Others >> Others Research Areas >> Inflammation/Immunology
In Vitro	Glatiramer acetate (25-100 mg/kg; S.c; 5 days) increase BDNF levels[3]. In huntington’s disease (HD) mouse model, the N171-82Q transgenic mouse line, which exhibits a more rapidly progressing disease course. Glatiramer acetate (1 mg/mouse; s.c.; 5×week) beginning at 8 weeks of age and continuing until 20 weeks of age, which is near the age of death due to the disease. Glatiramer acetate elicited improves performance on several motor function measures. Glatiramer acetate significantly improves the performance of N171-82Q transgenic mice at 15 weeks of age in the rotarod test measured over the course of 4 days[3].
References	[1]. McKeage K. Glatiramer Acetate 40 mg/mL in Relapsing-Remitting Multiple Sclerosis: A Review. CNS Drugs. 2015;29(5):425-432. [2]. Arnon R, et al. Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications. Proc Natl Acad Sci U S A. 2004;101 Suppl 2(Suppl 2):14593-14598. [3]. Corey-Bloom J, et al. Beneficial effects of glatiramer acetate in Huntington's disease mouse models: Evidence for BDNF-elevating and immunomodulatory mechanisms. Brain Res. 2017;1673:102-110. [4]. Aharoni R, et al. Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ [published correction appears in Proc Natl Acad Sci U S A. 2005 Aug 23;102(34):12288]. Proc Natl Acad Sci U S A. 2003;100(24):14157-14162.

Boiling Point	385.2ºC at 760mmHg
Melting Point	>239°C (dec.) (lit.)
Molecular Formula	(C₉H₁₁NO_3.C₆H₁₄N₂O_2.C₅H₉NO_4.C₃H₇NO₂)x_.xC₂H₄O₂
Molecular Weight	623.65000
Flash Point	186.7ºC
Exact Mass	623.30100
PSA	374.13000
LogP	2.14760
Vapour Pressure	1.27E-06mmHg at 25°C
Storage condition	2-8°C